Retatrutide, a new synthetic peptide that mimics the action of three satiety hormones, enables particularly significant weight loss according to results from advanced clinical trials.

noli's read

This finding is based on extremely solid and recent scientific evidence. In May 2026, the company Eli Lilly published the results of its phase 3 clinical trial, the TRIUMPH-1 study (a randomized controlled trial or RCT), demonstrating that retatrutide leads to an average weight reduction of up to 28.3% after 80 weeks of use. These figures confirm the promising results of the phase 2 trial (another RCT conducted by Dr. Ania Jastreboff and published in 2023 in the New England Journal of Medicine), which already showed an average weight loss of 24.2% over 48 weeks. The classification as a "peptide drug" is scientifically accurate, as the molecule is a chain of amino acids designed to mimic the action of three key hormones that regulate hunger and satiety. While this is a major advancement in weight management support, it should be noted that this molecule is still experimental and has not yet received regulatory approval for marketing. Finally, the long-term effects of this triple hormonal action require more extensive follow-up data beyond current trial protocols.

the sources

1. 1Wilding JPH et al. (STEP 1) 2021
2. 2Jastreboff AM et al. (SURMOUNT-1) 2022
3. 3Jastreboff AM et al. 2023
4. 4Wilding JPH et al. (STEP 1 extension) 2022